Article Details

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Rating of "Buy" from Analysts

Retrieved on: 2021-09-07 05:48:45

Tags for this article:

Click the tags to see associated articles and topics

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Rating of "Buy" from Analysts. View article details on hiswai:

Excerpt

BlackRock Inc. now owns 6,158,133 shares of the biopharmaceutical company's stock worth $208,946,000 after purchasing an additional 259,565 shares in the last ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up